Optimal Management of Histone Deacetylase Inhibitor –Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat
Recent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges given the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to use new therapeutic agents optimally. Panobinostat is the first histone deacetylase inhibitor approved for the treatment of multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 11, 2018 Category: Hematology Authors: Jamie D. Cavenagh, Rakesh Popat Tags: Review Article Source Type: research

Investigational Antibody –Drug Conjugates for Treatment of B-lineage Malignancies
Antibody –drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen–antibody interactions to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity and simultaneously minimize off-target toxicity. The earliest ADCs provided disappointing results in the clinic; however, the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and greater potency payloads led to improved ADCs. (Source: Clinical Lymphoma...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Alex F. Herrera, Arturo Molina Tags: Review Source Type: research

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients from the Polish Adult Leukemia Group (PALG) Registry
To the Editor, (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Joanna Gora-Tybor, Tomasz Sacha, Joanna W ącław, Joanna Niesiobędzka-Krężel, Olga Grzybowska-Izydorczyk, Ewa Mędraś, Izabela Dereń-Wagemann, Elżbieta Patkowska, Ilona Seferyńska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Tags: Letter to the Editor Source Type: research

Investigational Antibody-Drug Conjugates (ADCs) for the Treatment of B-Lineage Malignancies
Antibody-drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen-antibody interactions in order to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity while simultaneously minimizing off-target toxicity. The earliest ADCs provided disappointing results in the clinic, but the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and higher potency payloads led to improved ADCs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Alex F. Herrera, Arturo Molina Tags: Review Article Source Type: research

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients with Acute Myeloid Leukemia: A Systematic Literature Review
Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one-third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly ( ≥60 years old) patients with AML.Published literature on the topic was scant, and the review included only 22 articles examining outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller Tags: Review Article Source Type: research

Evaluation of parameters related to the probability of leukemic progression in patients with lower-risk myelodysplastic syndrome
Several prognostic factors such as intermediate karyotype, presence of 5-9% bone marrow blasts and platelet count (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 9, 2018 Category: Hematology Authors: Jose F. Falantes, Francisco J. M árquez-Malaver, Cristina Calderón-Cabrera, Begoña Pedrote, María L. Martino, Jose González, Ildefonso Espigado, Jose A. Pérez-Simón Tags: Original Study Source Type: research

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational  Study
In the present study, we identified 37 patients with chronic myeloid leukemia in 7 medical centers to study how ponatinib is used outside of clinical trials. At least 1 previous tyrosine kinase inhibitor had failed in all 37 patients. Their median age was 43 years (range, 9-82 years), and the overall response rate was 85%. Outside of clinical trials, ponatinib has been reserved for exceptionally young patients; however, responses can be expected even in heavily pretreated patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 7, 2018 Category: Hematology Authors: Adi Shacham-Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Helman, Liat Shargian, Anna Gourevitch, Evgeni Chubar, Roy Ratzon, Uri Rozovski Tags: Original Study Source Type: research

Real-life experience with ponatinib in chronic myeloid leukemia (CML): A multicenter observational study
To study how ponatinib is used outside clinical trials, we identified 37 patients with CML in 7 medical centers; all failed at least one prior TKI. The median age was 43 years (range: 9 - 82) and the overall response rate was 85%. Hence, in real-life, ponatinib is reserved for exceptionally young patients. Responses are expected even in heavily pretreated patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 7, 2018 Category: Hematology Authors: Adi Shacham-Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Helman, Liat Shargian, Anna Gourevitch, Evgeni Chubar, Roy Ratzon, Uri Rozovski Tags: Original Study Source Type: research

Surrogate Endpoints and Risk Adaptive Strategies In Previously Untreated Follicular Lymphoma
Follicular lymphoma is the second most common subtype of non-Hodgkin ’s lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in th e front-line setting. Long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus, clinical trials require approximately 5 to 8 years from activation to completion and analysis of outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2018 Category: Hematology Authors: M.S. Narkhede, B.D. Cheson Tags: Review Article Source Type: research

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
Connect MM is a large prospective observational US-based disease registry that was used to evaluate second-line treatment patterns in patients with relapsed or refractory multiple myeloma during a 5-year period, from 2010 to 2016. Treatment uptake was found to coincide with clinical milestones (ie, regulatory approvals, clinical study results), with growing preference for newer agents and triplet combinations over time. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E.Dawn Flick, Amit Agarwal, Robert M. Rifkin Tags: Original Study Source Type: research

Successful Use of Bortezomib –Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma
Plasmablastic lymphoma (PBL) is a rare type of non-Hodgkin lymphoma (NHL) with a predilection for the oral cavity. It is more commonly found in elderly patients infected with HIV and Epstein-Barr virus (EBV). Since PBL was first described in 1997,1 most cases have been described in HIV-positive patients.2 Some instances have been described in HIV-negative patients involving other organs; one third of these occurred in patients treated with some immunosuppressive therapy.3 The scarcity of presentations in HIV-negative patients and the overlapping features with multiple myeloma present a diagnostic and therapeutic challenge....
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: William D. Marrero, Alexis Cruz-Chac ón, Christian Castillo, Fernando Cabanillas Tags: Case Report Source Type: research

Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study
We performed a retrospective study to compare the hematologic response, organ response, and overall survival in patients with light chain amyloidosis, receiving bortezomib-based therapy before autologous stem cell transplantation (ASCT) versus non –bortezomib-based therapy or no therapy before ASCT. In the present study, although the patients who received bortezomib before transplantation were at greater risk at baseline, we found significantly better outcomes in these patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Tania Jain, Heidi E. Kosiorek, Shu T. Kung, Vishal S. Shah, Amylou C. Dueck, Veronica Gonzalez-Calle, Susan Luft, Craig B. Reeder, Roberta Adams, Pierre Noel, Jeremy T. Larsen, Joseph Mikhael, Leif Bergsagel, A. Keith Stewart, Rafael Fonseca Tags: Original Study Source Type: research

Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States
We performed a retrospective population-based study to determine the epidemiology of natural killer (NK)/T-cell neoplasms in the United States. We found that the incidence of NK/T-cell lymphoma doubled during the past decade and is more common in Hispanic population. Unlike NK/T-cell lymphoma, no significant racial disparities were found in NK/T-cell leukemia. The risk of second primary acute myeloid leukemia might be increased for patients with NK/T-cell lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Anuhya Kommalapati, Sri Harsha Tella, Apar Kishore Ganti, James O. Armitage Tags: Original Study Source Type: research

Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect ® MM Registry (2010–2016)
Connect ® MM is a large prospective observational US-based disease registry that was used to evaluate second-line treatment patterns in patients with relapsed or refractory multiple myeloma during a 5-year period, from 2010 to 2016. Treatment uptake was found to coincide with clinical milestones (i.e., reg ulatory approvals, clinical study results), with growing preference for newer agents and triplet combinations over time. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E. Dawn Flick, Amit Agarwal, Robert M. Rifkin Tags: Original Study Source Type: research

Treatment of vulvar mycosis fungoides tumors with localized radiotherapy
Primary cutaneous lymphomas are a heterogeneous group of lymphoid malignancies and are the second most common group of extranodal non-Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.1 NHL involving the female genitalia is unusual, posing diagnostic and therapeutic challenges.2-4 Rare cases of vulvar NHL presenting as a vulvar mass were mostly diagnosed as diffuse large B-cell lymphoma and had an aggressive course.3,5 Cases of cutaneous T-cell lymphoma (CTCL) involving the vulva have been rarely reported. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Shamir Geller, Ken Pitter, Alison Moskowitz, Steven M. Horwitz, Joachim Yahalom, Patricia L. Myskowski Tags: Case Report Source Type: research

Successful Use of Bortezomib Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma
Plasmablastic lymphoma (PBL) is an unusual disorder which shares some features with myeloma. The vast majority of cases have been reported in human immunodeficiency virus (HIV) positive patients. It usually presents in the oral cavity and is considered as an aggressive lymphoma with a very poor prognosis for which there is no standard of care. Despite treatment most of the patients have a suboptimal outcome. Here we present a case of PBL presenting in the parotid gland of an HIV negative patient who upon relapse responded well to a regimen that included bortezomib and lenalidomide, drugs with excellent activity in myeloma....
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: William D. Marrero, Alexis Cruz-Chac ón, Christian Castillo, Fernando Cabanillas Tags: Case Report Source Type: research

Treatment with Bortezomib Based Therapy Followed by Autologous Stem Cell Transplantation Improves Outcomes in Light Chain Amyloidosis: A retrospective study
In this study, although the patients who received bortezomib prior to transplantation were at higher risk at baseline, we found significantly better outcomes in these patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Tania Jain, Heidi E. Kosiorek, Shu T. Kung, Vishal S. Shah, Amylou C. Dueck, Veronica Gonzalez-Calle, Susan Luft, Craig B. Reeder, Roberta Adams, Pierre Noel, Jeremy T. Larsen, Joseph Mikhael, Leif Bergsagel, A Keith Stewart, Rafael Fonseca Source Type: research

NK/T-cell neoplasms: Analysis of incidence, patient characteristics and survival outcomes in the United States
This was a retrospective population-based study aimed to determine the epidemiology of NK/T-cell neoplasms in the United States. We noticed that the incidence of NK/T-cell lymphoma doubled over the past decade and is more common in Hispanic population. Unlike NK/T-cell lymphoma, no significant racial disparities exist in NK/T-cell leukemia. There may be an increased risk of second primary acute myeloid leukemia (AML) in patients with NK/T-cell lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2018 Category: Hematology Authors: Anuhya Kommalapati, Sri Harsha Tella, Apar Kishore Ganti, James O. Armitage Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 27, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 27, 2018 Category: Hematology Source Type: research

Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature
The purpose of the present study was to define the frequency of chromosomal abnormalities in 155 Moroccan patients with acute lymphoblastic leukemia referred to the BIOLAB Laboratory from the Children ’s Hospital of Rabat and compare our findings with those from reported studies. We identified chromosomal aberrations in 66% of the cases, of which 70% revealed recurrent abnormalities with high prognostic value that correlated with the reported data and their lineage. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2018 Category: Hematology Authors: Zahra Takki Chebihi, Aziza Belkhayat, Elbekkay Chadli, Latifa Hilal, Hanaa Skhoun, Laila Hessissen, Mohamed El Khorassani, Maria El Kababri, Amina Kili, Mohammed Khattab, Youssef Bakri, Nadia Dakka Tags: Original Study Source Type: research

Cytogenetic profile of Moroccan pediatric acute lymphoblastic leukemia (ALL): analysis of 155 cases with review of literature
Acute lymphoblastic leukemia (ALL) is the commonest malignancy in children, with a peak incidence of 2 to 3 years, accounting for almost 30% of all cancers in this age group.It is well established that the identification of cytogenetic abnormalities is highly relevant for prognosis and therapeutic decisions in ALL.The purpose of this study is to define the frequency of recurrent chromosomal abnormalities of ALL in Moroccan patients referred exclusively to BIOLAB laboratory from the children hospital of Rabat over a period of 4 years and compare our findings to the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2018 Category: Hematology Authors: Z. Takki Chebihi, A. Belkhayat, E. Chadli, L. Hilal, H. Skhoun, L. Hessissen, M. El Khorassani, M. El Kababri, A. Kili, M. Khattab, Y. Bakri, N. Dakka Source Type: research

Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective
Treatment-free remission after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal in patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. While guidance are now available, considering patients ’ questions on this progressive concept have yet to be addressed. The overall aim of this European Steering Group is a patient-centered approach that educates patients on their treatment options, including treatment-free remission, facilitates better patient-physician relationships, and meets pati ents’ emotional and psychological needs. (So...
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2018 Category: Hematology Authors: Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Nigel Deekes, Valentín Garcia-Gutiérrez, Jan de Jong, Šarūnas Narbutas, Peter Westerweel, Daniela Zackova Tags: Review Article Source Type: research

Cytogenetic profile of Moroccan pediatric acute lymphoblastic leukemia (ALL): analysis of 155 cases with review of literature
Acute lymphoblastic leukemia (ALL) is the commonest malignancy in children, with a peak incidence of 2 to 3 years, accounting for almost 30% of all cancers in this age group.It is well established that the identification of cytogenetic abnormalities is highly relevant for prognosis and therapeutic decisions in ALL.The purpose of this study is to define the frequency of recurrent chromosomal abnormalities of ALL in Moroccan patients referred exclusively to BIOLAB laboratory from the children hospital of Rabat over a period of 4 years and compare our findings to the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2018 Category: Hematology Authors: Z. Takki Chebihi, A. Belkhayat, E. Chadli, L. Hilal, H. Skhoun, L. Hessissen, M. El Khorassani, M. El Kababri, A. Kili, M. Khattab, Y. Bakri, N. Dakka Source Type: research

Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective
Treatment-free remission after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal in patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. While guidance are now available, considering patients ’ questions on this progressive concept have yet to be addressed. The overall aim of this European Steering Group is a patient-centered approach that educates patients on their treatment options, including treatment-free remission, facilitates better patient-physician relationships, and meets pati ents’ emotional and psychological needs. (So...
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2018 Category: Hematology Authors: Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Nigel Deekes, Valentín Garcia-Gutiérrez, Jan de Jong, Šarūnas Narbutas, Peter Westerweel, Daniela Zackova Tags: Review Article Source Type: research

Real-World Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
The Registry of Monoclonal Gammopathies (RMG) collects long-term data on patients with hematological malignancies and is one of the largest registries of its kind in Europe. This non-interventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into real-world treatment outcomes in patients with multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 16, 2018 Category: Hematology Authors: Roman H ájek, Jiri Jarkovsky, Vladimír Maisnar, Ludek Pour, Ivan Špička, Jiri Minařík, Evžen Gregora, Petr Kessler, Michal Sýkora, Hana Fraňková, Marco Campioni, Lucy DeCosta, Maarten Treur, Sebastian Gonzalez-McQuire, Walter Bouwmeester Tags: Original Study Source Type: research

Italian multicenter study on accuracy of 18F-FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin ’s Lymphoma
This study investigated the utility of F-18-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared to bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin ’s lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with 18F-FDG PET/CT presenting doubtful bone marrow findings. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 14, 2018 Category: Hematology Authors: A. Cistaro, L. Cassalia, C. Ferrara, N. Quartuccio, L. Evangelista, M. Bianchi, F. Fagioli, G. Bisi, S. Baldari, A. Zanella, M. Pillon, P. Zucchetta, M. Burei, A. Sala, L. Guerra, P. Guglielmo, R. Burnelli, S. Panareo, F. Scalorbi, I. Rambaldi, A. Piccard Tags: Original Study Source Type: research

Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma
A retrospective study was performed of 341 cases of extralymphatic Hodgkin lymphoma (HL) to identify its characteristics and outcomes. Sites were lung in 29 patients (44%), bone in 22 (33%), and liver in 5 (18%). Extralymphatic HL is a rare occurrence (16%) associated with poor clinical outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 13, 2018 Category: Hematology Authors: Francesco Gaudio, Pasquale Pedote, Artor Niccoli Asabella, Tommasina Perrone, Filomena Emanuela Laddaga, Paola Sindaco, Antonia Cimmino, Dario D'Abbicco, Angela Pezzolla, Giuseppe Rubini, Giorgina Specchia Tags: Original Study Source Type: research

Extralymphatic Disease Is An Independent Prognostic Factor In Hodgkin ’s Lymphomas
This study aims to identify the characteristics and outcomes of patients with extralymphatic HL. We performed a retrospective single institution study of 341 cases (207 (61%) males and 134 (39%) females) with a median follow-up of 44 months; 55 patients (16%) had extralymphatic disease. The sites were the lung in 29 patients (44%), bone in 22 (33%), liver in 5 (18%) and kidney in 3 (5%). In 46 patients (86%) only one organ was involved, while in 7 patients (13%) extralymphatic disease was present in 2 sites and in 2 patients (3%) in 3 sites. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 13, 2018 Category: Hematology Authors: Francesco Gaudio, Pasquale Pedote, Artor Niccoli Asabella, Tommasina Perrone, Filomena Emanuela Laddaga, Vito Pier Gagliardi, Antonia Cimmino, Dario D ’abbicco, Angela Pezzolla, Giuseppe Rubini, Giorgina Specchia Tags: Original Study Source Type: research

“Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions”—Treatment of ALL
The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible, whereas in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant benefits. (Sour...
Source: Clinical Lymphoma, Myeloma and Leukemia - April 2, 2018 Category: Hematology Authors: Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer Tags: SOHO State of the Art Updates and Next Questions Source Type: research

“SOHO State of the Art Updates and Next Questions” Treatment of ALL
The outcome of adult Acute Lymphoblastic Leukemia (ALL) has substantially improved by adopting pediatric inspired regimens, and about half of the patients are nowadays cured. The evaluation of Minimal Residual Disease (MRD) currently represents the most important prognostic which drive treatment algorithm and which includes allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, Stem Cell Transplantation (allo-SCT) should be pursued as soon as possible, while in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant ...
Source: Clinical Lymphoma, Myeloma and Leukemia - April 2, 2018 Category: Hematology Authors: Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Source Type: research

Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpoint inhibitors. These approaches have shown significant efficacy in clinical trials and might be associated with fewer long-term toxicities compared with c...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Steven M. Bair, Anthony Mato, Jakub Svoboda Tags: Review Source Type: research

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenstr öm Macroglobulinemia
We reviewed 55 patients with untreated symptomatic Waldenstr öm macroglobulinemia (WM) and prospectively evaluated their serum cytokines and biological markers. High circulating chemokine (C-C) motif ligand 3 (CCL-3) serum levels predicted shorter progression-free survival while high serum receptor activator of nuclear factor κB ligand levels predicted shor ter overall survival. This correlation reveals the importance of these cytokines in disease biology and highlights the significance of the interactions between WM and stromal cells for the development of WM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Dimitrios Christoulas, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Athanasios Papatheodorou, Meletios A. Dimopoulos, Evangelos Terpos Tags: Original Study Source Type: research

Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis
The objective of the study was to evaluate through meta-analysis the pooled proportions of patients responding to each therapeutic agent. We conducted a systematic review and meta-analysis to estimate the pooled response rate to modern hairy cell leukemia therapies. Articles published between January 1992 and August 2017 were identified by searching PubMed, Web of Science, and the Cochrane Library. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Iga Andrasiak, Justyna Rybka, Tomasz Wrobel Tags: Review Source Type: research

Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?
We retrospectively evaluated the clinical, cytogenetic, and molecular profiles, and survival outcomes of pediatric acute myeloid leukemias (AMLs) with and without myeloid sarcoma (MS). MS was present in 121 of 570 patients (21.2%). The most frequent site was the orbit. Event-free survival (P  = .003) and overall survival (P = .001) were better among AML with MS. The t (8; 21) was significantly associated with MS (odds ratio = 3.92). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Raja Pramanik, Anudishi Tyagi, Anita Chopra, Akash Kumar, Sreenivas Vishnubhatla, Sameer Bakhshi Tags: Original Study Source Type: research

Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study
The clinical significance of ferritin at diagnosis in patients with acute myeloid leukemia was examined in a multicenter retrospective study. Elevated ferritin may indicate tumor burden and predict worse event-free survival in the high-risk karyotype group. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Tags: Original Study Source Type: research

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenstr öm Macroglobulinemia
We reviewed 55 patients with untreated symptomatic Waldenstr öm macroglobulinemia (WM) and prospectively evaluated their serum cytokines and biological markers. High circulating chemokine (C-C) motif ligand 3 (CCL-3) serum levels predicted shorter progression-free survival while high serum receptor activator of nuclear factor κB ligand levels predicted shor ter overall survival. This correlation reveals the importance of these cytokines in disease biology and highlights the significance of the interactions between WM and stromal cells for the development of WM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Dimitrios Christoulas, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Athanasios Papatheodorou, Meletios A. Dimopoulos, Evangelos Terpos Tags: Original Study Source Type: research

Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Though the majority of patients are cured with standard frontline therapy, up to 20% of patients will have relapsed or refractory disease. Though the conventional approach to treatment has consisted of chemotherapy, radiation, and for those that relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpoint inhibitors. These approaches have demonstrated significant efficacy in clinical trials and may be associated with fewer long-term toxicities com...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Steven M. Bair, Anthony Mato, Jakub Svoboda Tags: Review Article Source Type: research

Circulating Soluble Receptor Activator of Nuclear Factor-kappa B Ligand and C-C Motif Ligand-3 Correlate with Survival in Patients with Waldenstr öm’s Macroglobulinemia
Serum nuclear receptor ligand kappa B (sRANKL) and chemokine (C-C) motif ligand-3 (CCL-3) have been reported to be elevated in Waldenstr öm’s macroglobulinemia (WM) patients. However, there are no published data regarding the prognostic value of these molecules in WM, regarding progression free survival (PFS) and overall survival (OS). To evaluate the effect of these markers of bone remodeling on survival parameters we evaluated p rospectively serum cytokines and biological markers in 55 patients with symptomatic WM, before receiving any kind of treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Dimitrios Christoulas, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Athanasios Papatheodorou, Meletios A. Dimopoulos, Evangelos Terpos Tags: Original Study Source Type: research

Response to the therapy in hairy cell leukemia: systematic review and meta-analysis
The objective of the study was to evaluate through meta-analysis the pooled proportions of patients responding to each therapeutic agent. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Iga Andrasiak, Justyna Rybka, Tomasz Wrobel Tags: Review Article Source Type: research

Myeloid sarcoma predicts superior outcome in pediatric AML; can cytogenetics solve the puzzle?
We retrospectively evaluated the clinical, cytogenetic, molecular profiles and survival outcomes of pediatric AMLs with and without myeloid sarcoma. MS was present in 121 of 570 patients (21.2%). Most frequent site was the orbit. EFS (p = 0.003) and OS (p = 0.001) were better among AML with MS. The t (8; 21) was significantly associated with MS (OR=3.92). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Raja Pramanik, Anudishi Tyagi, Anita Chopra, Akash Kumar, Sreenivas Vishnubhatla, Sameer Bakhshi Tags: Original Study Source Type: research

Clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia: A YACHT multicenter retrospective study
A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia. The study cohort included 305 patients who were newly diagnosed with AML from 2000 to 2015 and received standard induction chemotherapy. Transplantation was performed in 168 patients. The median ferritin value was 512 ng/mL (range: 8 –9,475). Ferritin correlated with lactate dehydrogenase, C-reactive protein, white blood cell count, and blast count, and elevation of ferritin was associated with poor performance status. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2018 Category: Hematology Authors: Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Tags: Original Study Source Type: research

Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma
Primary central nervous system lymphoma (PCNSL) accounts for   (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 19, 2018 Category: Hematology Authors: Colette Hanna, Diego Villa, Carla Irani, Marwan Ghosn, Elie El Rassy Tags: Case Report Source Type: research

Leukocytoclastic vasculitis and desensitization to high-dose methotrexate in primary central nervous system lymphoma
The backbone drug in the management of primary central nervous system lymphoma (PCNSL) is systemic high-dose methotrexate (HD MTX). This case report describes a previously healthy 56-year old man diagnosed with PCNSL who developed a severe leucocytoclastic vasculitis that was clinically consistent with HD MTX toxicity. He was given a premedication regimen along with a desensitization protocol for HD MTX that permitted the administration of additional cycles of HD MTX without further serious adverse events. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 19, 2018 Category: Hematology Authors: Colette Hanna, Diego Villa, Carla Irani, Marwan Ghosn, Elie El Rassy Tags: Case Report Source Type: research